Novanta Inc. (NOVT) Stock Analysis
Technology · Scientific & Technical Instruments
Sell if holding. Analyst target reached at $153.60 — A.R:R is negative (-0.3) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Sector modifier (Technology): -0.8.
Novanta Inc. is a global supplier of precision technology components for medical and advanced industrial OEMs across two segments: Automation Enabling Technologies ($500.8M revenue, laser beam steering, motion control, robotics) and Medical Solutions ($479.8M revenue,... Read more
Sell if holding. Analyst target reached at $153.60 — A.R:R is negative (-0.3) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Sector modifier (Technology): -0.8. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.1/10, moderate confidence.
Passes 7/9 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 76d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
Recent Developments — Novanta Inc.
Latest news
- Why Novanta Shares Are Suddenly Sliding Today - TipRanks — TipRanks negative
- Insider Selling: Novanta (NASDAQ:NOVT) CEO Sells 6,500 Shares of Stock - MarketBeat — MarketBeat negative
- Novanta (NOVT) CEO sells 6,500 shares under pre-set 10b5-1 trading plan - Stock Titan — Stock Titan negative
- Novanta (NOVT) CEO sells 6,500 shares in pre-set 10b5-1 trades - Stock Titan — Stock Titan negative
- Novanta Corporation Closing Their Mukilteo Location - My Everett News — My Everett News negative
Generated 2026-05-20T21:56:22Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMCustomertop-2 OEM medical customers10-K Item 1: 'two OEM customers, each operating primarily in the medical end market across multiple product lines, represented approximately 12% and 11%, respectively, of our consolidated revenue.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $153.60 — A.R:R is negative (-0.3) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Sector modifier (Technology): -0.8. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $142.85. Score 5.1/10, moderate confidence.
Take-profit target: $162.25 (+5.6% upside). Prior stop was $142.85. Stop-loss: $142.85.
Analyst target reached - limited upside remaining; Sector modifier (Technology): -0.8; Elevated risk factors.
Novanta Inc. trades at a P/E of 106.2 (forward 35.6). TrendMatrix value score: 4.8/10. Verdict: Sell.
10 analysts cover NOVT with a consensus score of 4.2/5. Average price target: $172.
What does Novanta Inc. do?Novanta Inc. is a global supplier of precision technology components for medical and advanced industrial OEMs across...
Novanta Inc. is a global supplier of precision technology components for medical and advanced industrial OEMs across two segments: Automation Enabling Technologies ($500.8M revenue, laser beam steering, motion control, robotics) and Medical Solutions ($479.8M revenue, insufflators, imaging, RFID, light engines). Revenue is earned from approximately 3,000 employees in 15+ countries selling proprietary components embedded in OEM customers' long-lifecycle systems. In 2025, two OEM medical customers represented approximately 12% and 11% of consolidated revenue, respectively.